EverHint – Momentum Swing — Pullback Standard for Feb 19, 2026 – 3 Signals – Basic Materials Leads (2)
3 signals. Basic Materials leads (2). 1 with insider selling. price range $12-$52. sectors: Basic Materials (2), Communication Services (1). full analyst coverage, earnings data, 66.7% have news
EverHint – Momentum Swing — Pullback Standard for Feb 11, 2026 – 4 Signals – Industrials Leads (3)
4 signals. Industrials leads (3). price range $14-$303. sectors: Industrials (3), Consumer Cyclical (1). full analyst coverage, earnings data, 50.0% have news.
EverHint Signal — Momentum Swing: Pullback Standard (9 stocks) — January 07, 2026
9 pullback signals detected—stocks that dipped below MA21 and reclaimed it on volume. Healthcare dominates (5 signals), but massive insider selling (-$16.7M) across IONS, AMGN, RVMD raises red flags. UMC earnings in 13 days.
EverHint Signal — Momentum Swing: Explosive Volume Breakout — January 05, 2026
10 explosive breakouts with 2.5x+ volume surge hit Jan 5th. Energy dominates: HAL, SLB, WFRD, SU surge on Venezuela news. Top signals: WFRD (93), FTAI (92), VICR (81). Institutional buying pressure confirms momentum. Mixed insider activity—heavy selling in energy names.
EverHint Signal — Momentum Swing: Pullback Standard — December 10, 2025
Six stocks reclaimed their 21-day moving averages after healthy pullbacks—NVST leads with perfect score, JPM dropped 5% on $105B expense warning but held MA21, and ABVX surged on Eli Lilly takeover speculation. Market showing strength with S&P +0.78%.
EverHint Signal — Momentum Swing: Tech Sector Breakout — November 21, 2025
One tech-sector breakout triggered today: GCT shows strong momentum, expanding volume, and high volatility near recent highs. Market backdrop was broadly risk-on with small caps outperforming and VIX easing but still elevated. This remains an experimental scanner.
EverHint Signal — Momentum Swing: Pullback Standard — November 21, 2025
Five stocks triggered Pullback Standard signals after reclaiming the MA21 on strong volume. Healthcare names dominate the list. Market backdrop turned risk-on with small caps surging and VIX easing but remaining elevated. This remains an experimental screen.
